TX-MARY-KAY
11.11.2020 02:02:04 CET | Business Wire | Press release
Mary Kay Inc. , a decades-long pioneer and innovator in skincare research, recently provided an educational grant to the International Master Course on Aging Science (IMCAS ) Academy to fund their highly anticipated webinar on “Office Peels and Home Peels” available to plastic surgeons, dermatologists, industry specialist, and aesthetic practitioners with the goal of continuing their education and improving practice.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110005239/en/
The webinar, which debuted worldwide to over 1,200 attendees, is just the latest event from the Academy whose mission is to provide leading education on the topic of aging science.
The webinar, moderated by IMCAS Academy Executive Editor, Dr. Dominique Du Crest, featured a renowned and diverse lineup of speakers from around the world. Mary Kay’s Dr. Michelle Hines, Director of Global Cosmetic Research & Innovation, kicked off the webinar with an overview of chemical peels and then joined experts to discuss various subjects surrounding a number of topics on the agenda. The topics covered the existential question of whether ‘to peel or not to peel’, different types of peels, peeling for darker skin types, the use of new and innovative ingredients, the dangers of peeling for patients with various skin diseases, with speakers also sharing tips on how to prolong the benefits of peeling post-procedure. The session concluded with a robust Q&A panel chaired by Dr. Uliana Gout, M.D. Alongside Dr. Hines, the featured speakers included Dr. Foteini Bageorgou, Dermatologist; Dr. Marina Landau, Dermatologist; and Dr. Mukta Sachdev, Dermatologist.
“Women of any age, anywhere in the world, want flawless skin,” said Dr. Hines. “Currently, chemical peels are a popular skin rejuvenation and skin resurfacing procedure. Professional and at-home peels offer different experiences and benefits. As there are many options available, education and awareness are important to make the best choice. Mary Kay was thrilled to provide a grant to further education and research on the topic.”
“I would like to underscore the dynamic and growing nature of our diverse community,” said Dr. Du Crest. “We have over 28,000 physician members, and with the outbreak of COVID-19, our community has expanded tremendously. Outside of our Congress, we offer webinars, sometimes twice a week, through which we create opportunities for doctors, physicians, dermatologists, and aestheticians all over the world to come together and share knowledge, expertise, and answer industry-related questions from their peers without having to travel or leave their home or office. Our e-Learning platform houses hundreds of clinical cases, numerous blog posts, over 40 webinars annually, and thousands of videos for industry professionals to be able to watch and enrich themselves on demand.”
The webinar was recorded and is available for viewing on the IMCAS Academy Library portal.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 57 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com
.
About International Course on Aging Science (IMCAS)
IMCAS was established in 1994 in Paris, France, as a congress dedicated to plastic surgeons and dermatologists. Since its inception, IMCAS has sought to bridge the knowledge gap between Plastic and Reconstructive Surgery and Dermatology, thereby generating synergies and helping bridge together these two fields. Its mission is to enable aesthetic practitioners to access quality scientific content on demand. IMCAS recently launched their e-learning platform, IMCAS Academy, which offers its subscribers instant access to instructional videos, scientific papers, expert interviews and more. For more information about IMCAS, click here: https://www.imcas.com/en
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005239/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom